Upregulated Ubiquitin D is a Favorable Prognostic Indicator for Rectal Cancer Patients Undergoing Preoperative Concurrent Chemoradiotherapy

CNU IR > Offices > 123 > Item 310902800/34672

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34672

Title:	Upregulated Ubiquitin D is a Favorable Prognostic Indicator for Rectal Cancer Patients Undergoing Preoperative Concurrent Chemoradiotherapy
Authors:	Chou, Chia-Lin Chen, Tzu-Ju Li, Wan-Shan Lee, Sung-Wei Yang, Ching-Chieh Tian, Yu-Feng Lin, Cheng-Yi He, Hong -Lin Wu, Hung-Chang Shiue, Yow-Ling Li, Chien-Feng Kuo, Yu-Hsuan
Contributors:	Chung Hua University Chi Mei Hospital Chi Mei Hospital Chi Mei Hospital National Sun Yat Sen University Chi Mei Hospital Chi Mei Hospital Chia Nan University of Pharmacy & Science Chi Mei Hospital I Shou University Chi Mei Hospital National Sun Yat Sen University Chi Mei Hospital National Health Research Institutes - Taiwan
Keywords:	hepatocellular-carcinoma increased expression protein fat10 gene progression metastasis
Date:	2022
Issue Date:	2023-12-11 14:04:15 (UTC+8)
Publisher:	DOVE MEDICAL PRESS LTD
Abstract:	Purpose: For locally advanced rectal cancer, neoadjuvant concurrent chemoradiotherapy (CCRT) allows tumor downstaging and makes curative radical proctectomy possible. However, we lack a genetic biomarker to predict cancer prognosis or treatment response. We investigated the association between ubiquitin D (UBD) expression and clinical outcomes in rectal cancer patients receiving CCRT. Patients and Methods: We analyzed the genes associated with the protein modification process (GO:0036211) and identified the UBD gene as the most relevant among the top 7 differentially expressed genes associated with CCRT resistance. We collected tissue specimens from 172 rectal cancer patients who had received CCRT followed by a curative proctectomy. We examine the relationship between UBD expression and patient characteristics, pathological findings, and patient survival, such as metastasis-free survival (MeFS) and disease-specific survival. Results: Upregulated UBD expression was associated with lower pre-CCRT tumor T stage (P = 0.009), lower post-CCRT tumor T stage (P < 0.001), lower post-CCRT nodal stage (P < 0.001), less vascular invasion (P = 0.015), and better tumor regression (P < 0.001). Using univariate analysis, we found that high UBD expression was correlated with better disease-free survival (DFS) (P < 0.0001), local recurrence-free survival (LRFS) (P < 0.0001) and MeFS (P < 0.0001). Moreover, multivariate analysis demonstrated that high UBD expression was associated with superior DFS (P < 0.001), LRFS (P = 0.01), and MeFS (P = 0.004). Conclusion: UBD upregulation was linked to better clinical prognosis, favorable pathological features, and good treatment response in rectal cancer patients undergoing CCRT. These results suggest UBD is a biomarker for rectal cancer.
Relation:	ONCOTARGETS AND THERAPY, v.15, n.CB2, pp.CC2, pp.-,
Appears in Collections:	[Offices] 123

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	134	View/Open

Loading...